EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 198 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... November 14, 2025 Inhibition of GDF-15 with Ponsegromab Results in Increased Weight Gain and... September 20, 2024 New Research in Treating Leukemia and Lymphoma: ASH Annual Meeting 2020 January 15, 2021 The Horror Story Of What Can Happen When You Don’t Pay... September 16, 2019 Load more HOT NEWS New insights on self-sampling for cervical cancer screening Virchow: The Largest Foundation Model for Computational Pathology To Date The incredible value of going public Making a startup out of a scientist
